Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 01:30:00 23/07/2026 am IST			5-day change	1st Jan Change
54.98 ^USD	-2.03%		-1.03%	+25.44%

13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT

Transcript : Exelixis, Inc. Presents at Stifel 2026 Targeted Oncology Virtual Forum, May-20-2026 01

Published on 05/21/2026 at 12:05 am IST - Modified on 05/21/2026 at 01:20 am IST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Stephen Willey (Analysts)

All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. And glad to have with us for the next session,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Exelixis, Inc.

13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
02/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Value-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Growth-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index	CI
22/06	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	CI
09/06	Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
03/06	Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:05 AM
01/06	Wall Street Starts June on Edge
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net	RE
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026	CI
28/05	Exelixis, Inc. Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-27-2026 03:30 PM